Michael McCullar, PhD, MBA, CEO, has >20 years of pharmaceutical experience in strategic planning and development, drug discovery and operation, business development and commercial operation. Previously he served as Chief Operating Officer at Tolero Pharmaceuticals, where he oversaw drug discovery & development activities as well as corporate development, and commercial planning. He played a major role in the acquisition of Tolero by Sumitomo Dainippon Pharma for $780M ($200M upfront). Prior to joining Tolero Pharmaceuticals, he held multiple roles at Astex Pharmaceuticals including SVP of Business Development where he was involved in the acquisition of Astex Pharmaceuticals by Otsuka for $886M in cash. In addition, he served as Vice President of Development and Operations and led the FDA approval of Dacogen for the treatment of MDS, while at SuperGen, Inc. He earned a PhD from University of California and MBA from the W.P. Carey School of Business, Arizona State University.